Savara Inc(SVRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:49 PM ET (Korea 10/31 08:49)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.58 | Insider Own | 49.88% | Shs Outstand | 205.4M | Perf Week | 14.22% |
| Market Cap | 0.99B | Forward P/E | - | EPS next Y | 38.58% | Insider Trans | -0.38% | Shs Float | 103.0M | Perf Month | -4.46% |
| Enterprise Value | 0.85B | PEG | - | EPS next Q | -0.16 | Inst Own | 67.23% | Short Float | 27.91% | Perf Quarter | -9.57% |
| Income | -0.14B | P/S | - | EPS this Y | -19.81% | Inst Trans | 1.54% | Short Ratio | 14.56 | Perf Half Y | -5.86% |
| Sales | 0.00B | P/B | 6.89 | EPS next 5Y | - | ROA | -78.28% | Short Interest | 28.74M | Perf YTD | -20.07% |
| Book/sh | 0.7 | P/C | 5.72 | EPS past 3/5Y | -28.87% 8.57% | ROE | -105.48% | 52W High | -31.19% ($7.01) | Perf Year | 12.09% |
| Cash/sh | 0.84 | P/FCF | - | Sales past 3/5Y | - | ROIC | -80.17% | 52W Low | 24.87% ($3.86) | Perf 3Y | 31.34% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -12.4% | Gross Margin | - | Volatility(W/M) | 6.56% 6.15% | Perf 5Y | 315.52% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.28 | Perf 10Y | -11.72% |
| Dividend Ex-Date | - | Quick Ratio | 10.13 | EPS Q/Q | -12.95% | Profit Margin | - | RSI (14) | 49.32 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.13 | Sales Q/Q | - | SMA20 | 1.88% ($4.73) | Beta | 0.3 | Target Price | $11.06 |
| Payout | - | Debt/Eq | 0.21 | Earnings | 2026/8/11 | SMA50 | -5.02% ($5.07) | Rel Volume | 0.72 | Prev Close | $4.95 |
| Employees | 70 | LT Debt/Eq | 0.21 | EPS/Sales Surpr. | -12.28% - | SMA200 | -10.6% ($5.39) | Avg Volume(3M) | 1.97M | Price | $4.82 |
| IPO | 2000/10/16 | Option/Short | Yes/Yes | Trades | 6076 | Volume | 1,411,877 | Change | -2.63% |
🫁 Savara (SVRA) is a US clinical-stage biotech company focused on rare respiratory diseases. Its lead asset is MOLBREEVI (molgramostim), an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) formulation being developed for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). It uses a proprietary nebulizer system to deliver the therapy directly to the lungs, pursuing a differentiated position in the rare lung disease space, which carries significant unmet medical needs.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
SVRA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -19.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +315.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
27.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #156 of 597 in the industry
Based on market cap of $990M.
FAQ
What kind of company is SVRA?
SVRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SVRA?
The market cap of SVRA is approximately $990M, ranking 2,580 within its sector.
What is the 52-week high and low for SVRA?
SVRA has recorded a 52-week high of $7.01 and a low of $3.86.
